A diverse biotechnology platform – optimising multiple drug discovery opportunities

A platform offering a revolutionary approach to therapeutics – to markets of substantial unmet medical need

Cancer & septic shock - two key focus areas of pharma M & A activity which combined are responsible for 40% (~20 million) of global deaths

Veyonda® has the potential to turn ‘COLD’ cancer tumours to ‘HOT’ – a highly sought outcome in the pharma industry

Lead drug candidate Veyonda® being developed as a potential treatment for a broad range of cancers

Run by a highly experienced management team in drug development and product commercialisation.